Project Grant R43HL174376
Award Date
9/27/24
Completion Date
9/26/25
Dollars Obligated
$294K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Houston, TX 77021, USA
Similar Awards
The National Heart Lung and Blood Institute (NHLBI) awarded a $810,650 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to Cedars-Sinai Medical Center. The funding will support the development and validation of an artificial intelligence (AI)-enabled algorithm to characterize fibrotic and calcific aortic valve tissue from computed tomography angiography (CTA) scans. The goal is to predict rapid aortic valve disease progression and create an AI-powered risk score to predict...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,027,737 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to 3DT Holdings, LLC, a minority-owned biomedical engineering company. The objective of this "fast-track" proposal is to develop and validate a machine learning (ML)-based software tool for optimizing MitraClip placement procedures and predicting key outcomes like mitral regurgitation, left atrial pressure, and cardiac tissue...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $295,153 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Safebeat RX Inc. The funding supports the development of a novel, smartwatch-enabled technology that allows patients with low-risk atrial fibrillation to safely initiate antiarrhythmic medications at home. The technology analyzes post-drug ECG data taken by patients using a machine learning algorithm and provides this information to...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $443,544 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Dasisimulations LLC, a minority-owned small business located in Dublin, Ohio. The grant supports the development and validation of an innovative, AI-driven software platform to automatically perform complex measurements for pre-planning transcatheter aortic valve replacement (TAVR) procedures. The project aims to (1) develop and validate the...
The U.S. National Heart, Lung, and Blood Institute (NHLBI) awarded a $802,500 Cooperative Agreement grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Children's Hospital Medical Center in Cincinnati, Ohio. The grant supports the construction of a multi-scale 3D AI-powered map of genetic factors and cellular interactions driving normal and aberrant lung development in childhood interstitial lung disease (CHILD). The project will leverage single-cell and spatial...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $691,326 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Northwestern University to develop a "4D Right-Heart Virtual Catheter (4D VCATH)". This novel technology combines advanced mathematical modeling and 4D flow MRI to provide a comprehensive, non-invasive hemodynamic analysis of the right heart chambers. The project aims to enable streamlined diagnosis, classification, and prognosis...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $269,922 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Steth X Microsystems Inc. to develop a smart, wearable contact microphone patch for extended and remote monitoring of lung functions. The goal is to create a low-profile, battery-powered wireless device capable of accurately detecting and quantifying adventitious lung sounds as well as breathing abnormalities in patients with respiratory...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $167,588 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to the Icahn School of Medicine at Mount Sinai (ISMMS). The grant, awarded on March 1, 2025, with a completion date of February 28, 2030, will support the career development of Dr. Son Duong, a clinician-scientist specializing in pediatric cardiology and advanced cardiovascular imaging. The primary objectives are to: 1) Develop and validate a...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $400,000 Project Grant to Electronic Biosciences, Inc. on Sep 20, 2024. The grant supports the development of an innovative analytical testing device to quantitatively characterize lipoprotein particles in blood. This technology will enable rapid, precise, and cost-effective measurement of lipoprotein size, concentration, and other physical properties, which are...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $704,611 to The Trustees of Columbia University in the City of New York to validate the accuracy of the EchoNext deep learning model in detecting undiagnosed structural heart disease from electrocardiograms. The 5-year study aims to: 1) prospectively validate EchoNext's accuracy in detecting undiagnosed structural heart disease, 2)...